D-0235-2022 Class III Terminated

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-0235-2022 was initiated by Teva Pharmaceuticals USA on Oct 28, 2021 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications The recall status is terminated (terminated Feb 27, 2023). Affected quantity: 64,978 patches.

Recall details

Product Type
Drugs
Report Date
Nov 24, 2021
Initiation Date
Oct 28, 2021
Termination Date
Feb 27, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
64,978 patches

Product description

Clonidine Transdermal System, USP 0.1 mg/day, 4 patches per carton, Rx only, Manufactured by: Actavis Laboratories, UT Inc., Salt Lake City, UT, Distributed by: Actavis Pharma, Inc., Parsippany, NJ NDC 0591-3508-04

Reason for recall

Failed Impurities/Degradation Specifications

Distribution pattern

Nationwide and Puerto Rico

Code information

Lot# 1369117B, exp. date 11/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0235-2022
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0235-2022. Report a data issue: hello@regdatalab.com.